On Wednesday, Lennar Corporation (NYSE:LEN)’s shares inclined 0.49% to $47.28.
Lennar Corporation (LEN) has pulled back in the last week, but traders apparently believe that any further losses will be limited.
optionMONSTER’s tracking systems identified the sale of 2,300 July 43 puts in one print for the bid price of $0.60 this morning. This is clearly a new position, as open interest in the strike was a mere 10 contracts before the trade occurred.
The put seller collects the $0.60 premium and is looking for TICKER to stay above $43 through expiration in mid-July. If the stock falls below that strike price, the trader will be on the hook to buy shares at that level.
LEN is down 0.63 percent to $47.10 recently. The homebuilder rallied above $50 about a week ago with strong housing starts but hit resistance at its 50-day moving average and has been falling since.
Recently put selling makes up more than 80 percent of the option volume in Lennar, which already matches its full-session average for the last month.
Lennar Corporation, together with its auxiliaries, engages in the homebuilding activities in the United States. The company operates through Homebuilding East, Homebuilding Central, Homebuilding West, Homebuilding Southeast Florida, Homebuilding Houston, Financial Services, Rialto, and Lennar Multifamily segments. Its homebuilding activities primarily comprise the construction and sale of single-family attached and detached homes to first-time, move-up, and active adult homebuyers, in addition to the purchase, development, and sale of residential land.
Schlumberger Limited. (NYSE:SLB)’s shares dropped -0.16% to $91.35.
OneSubsea®, a Cameron (CAM) and Schlumberger (SLB) company, has been awarded a subsea production systems contract totaling more than $330 million for a gas project offshore North Africa.
The scope of supply for the 13-well development comprises subsea production equipment, tooling, and installation and commissioning services. Deliveries are predictable to start Q3 2016.
Schlumberger Limited supplies technology, integrated project administration, and information solutions to the oil and gas exploration and production industries worldwide. The company operates through Reservoir Characterization Group, Drilling Group, and Production Group segments.
At the end of Wednesday’s trade, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)‘s shares dipped -2.23% to $0.290.
AEterna Zentaris Inc. (USA) (AEZS) declared that it has received written scientific advice from the European Medicines Agency (“EMA”) regarding the further development plan, counting the study design, for the new confirmatory Phase 3 clinical study of Macrilen™ (macimorelin) for use in evaluating adult growth hormone deficiency (“AGHD”), following a Scientific Advice Meeting that was held earlier this month. As a result of the advice, the Company believes that the confirmatory Phase 3 study that was talk about with the U.S. Food & Drug Administration (“FDA”) last March, meets the EMA’s study-design expectations.
Study design
The multinational confirmatory efficacy Phase 3 clinical study with Macrilen™ for the evaluation of AGHD will be conducted as a two-way crossover study with the insulin tolerance test as the benchmark comparator. The study population will comprise of patients with a medical history documenting risk factors for AGHD and will comprise a spectrum of patients from those with a low risk of having AGHD to those with a high risk of having the condition. The Company will submit a projected final protocol to the FDA for their review prior to commencing the confirmatory efficacy Phase 3 study. A dedicated thorough Phase 3 QT study to evaluate the effect of Macrilen™ on myocardial repolarization is predictable to be initiated in early 2016.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
Mylan NV (NASDAQ:MYL), ended its Wednesday’s trading session with 0.15% gain, and closed at $72.39.
Mylan NV (MYL) declared that the Company will present at Goldman Sachs 36th Annual Global Healthcare Conference on Tuesday June 9, 2015. The presentation is planned to start at 4 p.m. PT / 7 p.m. ET.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
